Posted on February 1, 2019 by Sitemaster
The Prostate Cancer Foundation (PCF) has just published the 2019 update to its Prostate Cancer Patient Guide, which is a very useful (and free) introduction to prostate cancer for patients and their caregivers. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: cancer, Foundation, guide, patient, PCF, prostate | Leave a comment »
Posted on January 31, 2019 by Sitemaster
According to a media release issued late yesterday by Johnson & Johnson, the combination of apalutamide (Erleada) + androgen deprivation therapy (ADT) has met the primary study endpoints in the so-called TITAN trial. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, castration-sensitive, Erleada, hormone-sensitive, mCSPC, metastatic, mHSPC, outcome, TITAN, trial | Leave a comment »
Posted on January 30, 2019 by Sitemaster
The results of a small, randomized, double-blind, placebo-controlled trial to evaluate the role of curcumin in prostate cancer patients already treated on intermittent androgen deprivation therapy (IADT) have recently been published. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adbrogen, curcumin, deprivation, duration, IADT, intermittent, recurrence, tim | 8 Comments »
Posted on January 17, 2019 by Sitemaster
For many years researchers have been trying to identify so-called “surrogate” endpoints that can be used to predict overall and prostate cancer-specific survival with high accuracy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: endpoint, outcome, predictive, surrogate, survival, trial | 1 Comment »
Posted on January 17, 2019 by Sitemaster
Yesterday, Janssen Pharmaceuticals announced the approval of apalutamide (Erleada) by the European Commission (EC) for the treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC) who are at high risk for development of metastatic disease. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: apalutamide, approval, castration-resistant, Erleada, EU, Europe, nmCRPC, non-metastatic | 2 Comments »
Posted on January 14, 2019 by Sitemaster
It will hardly come as a surprise to most prostate cancer support group leaders and other prostate cancer advocates that there is a strong association between patient age and risk for side effects of radical prostatectomy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: complication, outcome, radical prostatectomy, surgery | 4 Comments »
Posted on January 10, 2019 by Sitemaster
A newly published paper in the Journal of Clinical Oncology has confirmed — based on a prospective study (as opposed to retrospective data) — that there is a strong risk association between a germline mutation of the BRCA2 gene and risk for metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: BRCA2, germline, mutation, screening | 1 Comment »